Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
PHAT on Nasdaq
Shares outstanding
69,596,826
Price per share
$16.59
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
62,337,214
Total reported value
$733,708,081
% of total 13F portfolios
0%
Share change
+4,917,671
Value change
+$59,003,862
Number of holders
132
Price from insider filings
$16.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Frazier Life Sciences Public Fund, L.P. 8.6% 0% $70,447,299 5,985,327 0% James N. Topper 01 Nov 2025
MILLENNIUM MANAGEMENT LLC 7.1% +20% $59,808,678 +$10,839,417 5,081,451 +22% Millennium Management LLC 30 Sep 2025
Carlyle Group Inc. 4.9% $30,142,485 3,496,808 Carlyle Group Inc. 28 Aug 2025
BlackRock, Inc. 4.6% $14,066,607 3,226,286 BlackRock, Inc. 31 Mar 2025
PRUDENTIAL FINANCIAL INC 0% -100% $8,705 -$24,547,397 2,630 -100% PRUDENTIAL FINANCIAL INC 31 May 2025

As of 30 Sep 2025, 132 institutional investors reported holding 62,337,214 shares of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT). This represents 90% of the company’s total 69,596,826 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 18% 12,466,489 0% 4.4% $146,730,576
Medicxi Ventures Management (Jersey) Ltd 11% 7,464,572 0% 12% $87,858,012
MILLENNIUM MANAGEMENT LLC 7.3% 5,081,451 +126% 0.05% $59,808,678
Invesco Ltd. 5.6% 3,864,971 -6.6% 0.01% $45,490,710
Carlyle Group Inc. 5% 3,496,808 0% 0.95% $41,052,526
BlackRock, Inc. 4.9% 3,402,324 +2.6% 0% $40,045,354
VANGUARD GROUP INC 4.6% 3,215,572 +15% 0% $37,847,282
Ensign Peak Advisors, Inc 3.6% 2,503,344 -0.66% 0.05% $29,464,359
NEA Management Company, LLC 2.8% 1,960,169 0% 1.3% $23,071,189
683 Capital Management, LLC 2.6% 1,820,380 -14% 1.9% $21,425,873
WASATCH ADVISORS LP 2.2% 1,537,218 +5.2% 0.1% $18,093,056
Catalys Pacific, LLC 1.7% 1,167,114 0% 3.9% $13,736,932
GW&K Investment Management, LLC 1.6% 1,144,330 +9.1% 0.12% $13,469,000
Catalio Capital Management, LP 1.6% 1,128,521 +68% 2.5% $13,282,692
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,088,910 +1.8% 0% $12,819,107
STATE STREET CORP 1.5% 1,053,591 +24% 0% $12,400,766
MOORE CAPITAL MANAGEMENT, LP 0.86% 600,000 0% 0.14% $7,062,000
AMERIPRISE FINANCIAL INC 0.8% 554,590 +207% 0% $6,527,524
Propel Bio Management, LLC 0.79% 552,927 -40% 6.5% $6,507,951
CITADEL ADVISORS LLC 0.73% 508,720 0% $5,987,634
AIGH Capital Management LLC 0.62% 429,000 1.8% $5,049,330
StepStone Group LP 0.61% 422,085 0% 2.5% $4,967,940
SummitTX Capital, L.P. 0.55% 385,968 0.19% $4,542,843
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.53% 365,904 +1.6% 0% $4,306,690
NORTHERN TRUST CORP 0.51% 357,578 -0.49% 0% $4,208,694

Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 181,949 $3,018,850 +$1,906,306 $16.59 8
2025 Q3 62,337,214 $733,708,081 +$59,003,862 $11.77 132
2025 Q2 57,415,787 $550,618,405 -$26,654,537 $9.59 117
2025 Q1 64,025,009 $401,391,744 -$24,944,522 $6.27 136
2024 Q4 66,610,653 $540,837,976 -$121,495,122 $8.12 141
2024 Q3 72,636,064 $1,312,668,227 +$264,199,549 $18.08 133
2024 Q2 58,109,780 $598,557,394 +$27,856,700 $10.30 113
2024 Q1 55,378,949 $588,085,973 +$14,631,856 $10.62 112
2023 Q4 54,112,686 $503,299,407 +$11,390,968 $9.13 115
2023 Q3 43,760,270 $452,721,621 +$5,267,236 $10.37 109
2023 Q2 42,778,866 $612,591,768 +$176,400,941 $14.32 103
2023 Q1 30,786,694 $219,689,484 +$28,315,357 $7.14 83
2022 Q4 28,212,747 $316,546,824 -$21,719,929 $11.22 83
2022 Q3 30,185,827 $334,342,526 +$38,042,890 $11.08 87
2022 Q2 27,258,631 $230,064,222 +$9,335,400 $8.44 88
2022 Q1 25,654,888 $349,117,442 -$176,036,740 $13.61 74
2021 Q4 28,574,214 $561,954,045 +$49,942,191 $19.67 82
2021 Q3 25,543,470 $819,833,454 +$19,152,056 $32.10 81
2021 Q2 24,918,954 $843,508,479 +$13,169,188 $33.85 76
2021 Q1 24,475,818 $919,193,673 +$1,760,408 $37.56 82
2020 Q4 24,534,138 $815,024,391 +$96,707,884 $33.22 75
2020 Q3 21,632,831 $793,536,439 -$7,640,662 $36.67 57
2020 Q2 21,847,152 $718,752,879 -$3,025,534 $32.91 59
2020 Q1 21,949,381 $565,607,078 +$3,219,839 $25.82 47
2019 Q4 21,809,755 $677,010,000 +$593,409,007 $31.14 40